Replies to post #21880 on Relief Therapeutics Holding AG (RLFTF)

[dmsrz8]

Wait is it 8 of 30 survived or 22/30? Want everyone to get that clear. If it was indeed only 8/30 survived vs 19/21, then this could truly be huge

[nelskof]

I think you meant Emergency Use Authorization. These terms are all too similar.

They already have Expanded Access Protocol so it's interesting they are asking for EUA on the patients in the worst situation (no medical alternative). Those patients can already get the drug but this would certainly get a different level of exposure. More doctors would prescribe it and not have to jump through hoops.

My guess is they go back to the FDA and ask for another EUA on less severe patients after the trial results.

Thank you again for reporting back.

[r_deckard]

Thanks for this important confirmation!

[Millstone]

Thanks for relaying this timely information djhfsu!

They have added a control group to the pre-print study, which is often done after peer-review to bolster the study prior to potential publication. The addition of the control group further indicates that Aviptadil is far superior to SOC in this critical population.

My take #1: Aviptadil WILL be given an EUA for critical;

My take #2: The data so far is a home run. Lives will be saved, and the stock will quadruple in the near term;

My take #3: In the medium term (within 2 months) RLFTF should hit $4 per share.

After this, my crystal ball gets foggy.